POTELIGEO® Points virtual detailing library

Take a virtual tour of all things POTELIGEO with these short, information-packed vignettes.

The MAVORIC trial patient population
How POTELIGEO uniquely targets CCR41
POTELIGEO efficacy in skin1
Long-term safety follow-up
POTELIGEO efficacy in blood1

The MAVORIC trial patient population

Explore the diverse patient population and key efficacy results of POTELIGEO vs vorinostat.1

POTELIGEO efficacy in skin

Learn about the response of POTELIGEO in skin, based on a post-hoc analysis of data in the MAVORIC clinical trial.1

POTELIGEO efficacy in blood

Look at the response of POTELIGEO in the blood, based on a post-hoc analysis of data in the MAVORIC clinical trial.1

How POTELIGEO uniquely targets CCR4

Learn about the role of C-C chemokine receptor type 4 (CCR4) in mycosis fungoides (MF) and Sézary syndrome (SS), and how POTELIGEO kills CCR4+ malignant T-cells.1

Long-term safety follow-up

See the results of post-MAVORIC trial analysis of safety in patients with POTELIGEO treatment exposure up to 5 years.

Get downloadable resources

Easily access a wide array of downloadable brochures, forms, and fact sheets covering prescribing, reimbursement, and patient support.

Select downloads

Stay connected

Be sure to sign up so we can keep you informed of updates and new materials in the POTELIGEO Digital Library.

Stay up to date
POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

SEE MORE

Warnings and Precautions

  • Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
  • Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.
  • Infections: Monitor patients for signs and symptoms of infection and treat promptly.
  • Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.
  • Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

Adverse Reactions

  • The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).
  • You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This website uses cookies to personalize content, save your preferences, and track its performance. By continuing to use this website, you consent to the use of these cookies.
Terms of Use   |   Privacy Policy   |   Contact Us   |   Sitemap
Full Prescribing information   |   References
POTELIGEO is a registered trademark of
Kyowa Kirin Co., Ltd.
© 2020 Kyowa Kirin, Inc. All rights reserved.
PM-US-POT-0042 November 2020